Loading...
XASEMTNB
Market cap112mUSD
Dec 23, Last price  
0.52USD
1D
-4.57%
1Q
-85.47%
Jan 2017
-99.26%
IPO
-99.20%
Name

Matinas BioPharma Holdings Inc

Chart & Performance

D1W1MN
XASE:MTNB chart
P/E
P/S
103.10
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-46.39%
Rev. gr., 5y
55.71%
Revenues
1m
-65.62%
000194,4940149,687119,75090,000158,33333,3333,188,0001,096,000
Net income
-23m
L+76.27%
-116,075-3,713,127-10,221,045-9,135,400-7,598,737-15,486,489-14,083,073-15,585,184-20,598,962-21,173,454-13,015,000-22,942,000
CFO
-15m
L-20.24%
-57,264-2,987,837-7,961,196-7,814,403-6,118,723-11,459,437-10,321,209-14,092,066-17,367,836-15,223,455-19,156,000-15,278,000
Earnings
Mar 25, 2025

Profile

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
IPO date
Jun 03, 2014
Employees
34
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,096
-65.62%
3,188
9,464.10%
33
-78.95%
Cost of revenue
39,351
44,456
25,550
Unusual Expense (Income)
NOPBT
(38,255)
(41,268)
(25,516)
NOPBT Margin
Operating Taxes
(7,982)
(2,110)
Tax Rate
NOPAT
(38,255)
(33,286)
(23,406)
Net income
(22,942)
76.27%
(13,015)
-38.53%
(21,173)
2.79%
Dividends
(843,600)
Dividend yield
7.95%
Proceeds from repurchase of equity
99
6,996
BB yield
0.00%
-0.07%
Debt
Debt current
1,322
569
560
Long-term debt
6,451
7,679
8,846
Deferred revenue
(341)
(341)
Other long-term liabilities
341
341
Net debt
(5,983)
(20,715)
(40,217)
Cash flow
Cash from operating activities
(15,278)
(19,156)
(15,223)
CAPEX
(218)
(892)
(260)
Cash from investing activities
13,242
4,877
16,770
Cash from financing activities
(7)
79
6,965
FCF
(36,014)
1,332,434
1,480,642
Balance
Cash
13,756
28,763
49,622
Long term investments
200
Excess cash
13,701
28,804
49,620
Stockholders' equity
(175,772)
(153,433)
(131,758)
Invested Capital
199,235
194,194
188,954
ROIC
ROCE
EV
Common stock shares outstanding
4,345
216,811
210,178
Price
10.81
-56.76%
25.00
-50.50%
50.50
-25.74%
Market cap
46,973
-99.13%
5,420,286
-48.93%
10,614,006
-20.72%
EV
40,990
5,399,571
10,573,789
EBITDA
(37,314)
(40,370)
(24,735)
EV/EBITDA
Interest
3,593
Interest/NOPBT